

A solid orange vertical bar on the left side of the page.

# Axion BioSystems **ESG Report 2024**

# Table of Contents

1.1. Introduction.....	2
1.2. Supporting the UN Agenda for Sustainable Development.....	2
1.2.1. SDG 3 Good Health and Well-Being.....	3
1.2.2. SDG 5 Gender Equality.....	3
1.2.3. SDG 9 Industry, Innovation, and Infrastructure.....	4
1.2.4. SDG 12 Responsible Consumption and Production.....	4
1.2.5. SDG 13 Climate Action.....	5
1.3. Current Year Emissions.....	5
1.4. Contact Information.....	6

## 1.1. Introduction

Axion BioSystems is a global life science tools business developing, producing, and commercializing BEA (Bioelectronic Assay) and live-cell imaging instruments for customers across pharma, biotech, and academia. The company's products enable multi-dimensional, interoperable live-cell analysis to improve drug discovery and development.

Understanding cell behavior is central to some of the most important segments of pharmaceuticals, including the development of new therapeutics and understanding drug safety.

People and the planet are the heart of Axion BioSystems. We recognize our responsibility to uphold sustainable business practices and strive to align our business operations with the latest climate science.

In our ESG initiatives, we define sustainability as striking a balance between current and future social, economic, and environmental needs. As such, we strive to maximize our sustainable development while satisfying the growing demand for life science products.



## 1.2. Supporting the UN Agenda for Sustainable Development



We strive to align our operations with the United Nations 2030 Agenda for Sustainable Development and support each of the 17 Sustainable Development Goals (SDGs). We are highlighting five of the SDGs which our business especially works to support.



### 1.2.1. SDG 3 GOOD HEALTH AND WELL-BEING

Goal	Action
<p>3.4 Reduce mortality from non-communicable diseases and promote mental health</p> <p>3.4.1 Mortality rate attributed to cardiovascular disease, cancer, diabetes, or chronic respiratory disease</p>	<p>1/6 deaths are due to cancer globally, making it one of the leading causes of death worldwide. Axion enables multi-dimensional, interoperable live-cell analysis to improve drug discovery and development, driving breakthroughs in cell and gene therapies, ultimately leading to superior health outcomes.</p> <p>Axion's products enable scientists to better understand cell function in real time, enabling research and the development of new therapies across various pharmaceutical segments and applications. Without Axion, academia and biopharma would have less insight into cell function, slowing down the time, increasing the cost, and reducing the quality of critical drug development.</p>



### 1.2.2. SDG 5 GENDER EQUALITY

Goal	Action
<p>5.5 Ensure full participation in leadership and decision-making</p>	<p>Target: 40% of board is female by 2024</p> <p>Currently, 33% of the board is female.</p>



### 1.2.3. SDG 9 INDUSTRY, INNOVATION, AND INFRASTRUCTURE

Goal	Action
9.2 Promote inclusive and sustainable industrialization	Axion enables academia and biopharma to gain insights into cell function, and thereby contributes to speeding up the time and increasing the quality of critical drug development.
9.4 Upgrade all industries and infrastructures for sustainability	
9.5 Enhance research and upgrade industrial technologies	



### 1.2.4. SDG 12 RESPONSIBLE CONSUMPTION AND PRODUCTION

Goal	Action
12.2 Sustainable management and use of natural resources	Axion is committed to minimizing or eliminating the use of environmentally harmful materials. We ensure any remaining hazardous waste is responsibly managed.
12.4 Responsible management of chemicals and waste	
12.5 Substantially reduce waste generation	89 tCO <sub>2</sub> e per EUR m revenue (low carbon intensity)
12.6 Encourage companies to adopt sustainable practices and sustainability reporting	



## 1.2.5. SDG 13 CLIMATE ACTION

Goal	Action
13.2 Integrate climate change measures into policy and planning	<p>In 2023, Axion received an official validation of their Science Based Targets. Axion commits to reduce scope 1 and scope 2 GHG emissions 42% by 2030 compared to 2022 as base year, and to measure and reduce its scope 3 emissions.</p> <p>So far reduced Scope 1 &amp; 2 emissions by 37% and 18% respectively</p>

### 1.3. Current Year Emissions


Axion Biosystems conducted our first emissions inventory in 2021 and has continued to measure our emissions annually. Our emissions accounting includes emissions from our own operations and our value chain (Scope 1-3 GHG emissions). To calculate our emissions, we work with Normative, a science-based carbon accounting engine and analytics provider.

Axion’s emission inventory is divided into the following categories, as defined by the Greenhouse Gas Protocol:

- **Scope 1:** direct emissions from Axion-owned sources
- **Scope 2:** indirect emissions generated by purchased electricity, heating, and steam
- **Scope 3:** indirect emissions not included in scope 2, such as upstream and downstream value chain emissions, commuting, and business travel.

Below is an outline of the most up to date accounting and breakdown of Axion Biosystems' emissions and carbon footprint.

## Axion BioSystems' carbon footprint, 2023 (2046 tCO<sub>2e</sub>)



To achieve our emission reduction targets, Axion established an internal ESG council, which oversees our sustainability policy and implementation. In 2023, Axion conducted site audits to identify material ESG growth opportunities, which led to a 37% and 18% reduction in Scope 1 and Scope 2 emissions, respectively, putting us ahead of our 2030 reduction target.

### 1.4. Contact Information

For more information regarding the Science Based Targets Initiatives can be found at the following link: <https://sciencebasedtargets.org/>

#### Published by

Axion BioSystems  
 1819 Peachtree Rd. NE  
 Suite 350  
 Atlanta, GA 30309

#### Contact

Jared Williams, PhD  
 Staff Process Engineer  
[jwilliams@axionbio.com](mailto:jwilliams@axionbio.com)

#### Publish Date

July, 2024